NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) and its subsidiary HOPE Therapeutics have announced their participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The event will be held at the Lotte New York Palace Hotel and will also offer virtual participation options. Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will present an overview of the company's business during the conference.

Institutional investors can register for the conference through the provided link. The presentation will be available on-demand starting September 9 at 7:00 A.M. (ET) and can also be accessed through the company's investor relations website.

Positive

• Participation in a major investment conference, potentially increasing visibility to investors
• Presentation by the company's Chairman and Chief Scientist, offering high-level insights

Negative

• None.

MIAMI, Sept. 3, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company") and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a presenting companies at the H.C. Wainwright 26^th Annual Global Investment Conference.  The conference is being held on September 9-11, 2024. 

The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue.  Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.

Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will provide an overview of the Company's business during the presentation.

If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.   

Event:  H.C. Wainwright 26^th Annual Global Investment Conference

Date:  September 9-11, 2024

Location:  Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person at the Lotte New York Palace Hotel, New York, NY.

Access to the presentation can also be found at https://ir.nrxpharma.com/events beginning at 7:00AM ET Monday September 9, 2024.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About H.C. Wainwright & Co. 

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors.  According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com  

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information: 

CORPORATE CONTACTS: 
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com 

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-announce-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-september-9-11-2024-302236168.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When is NRx Pharmaceuticals (NRXP) presenting at the H.C. Wainwright Global Investment Conference?

NRx Pharmaceuticals (NRXP) will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, which is scheduled for September 9-11, 2024. The presentation will be available on-demand starting September 9 at 7:00 A.M. (ET).

Who will be presenting for NRx Pharmaceuticals (NRXP) at the H.C. Wainwright conference?

Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will provide an overview of the company's business during the presentation at the H.C. Wainwright conference.

Where can investors access NRx Pharmaceuticals' (NRXP) presentation from the H.C. Wainwright conference?

Investors can access NRx Pharmaceuticals' (NRXP) presentation from the H.C. Wainwright conference through the company's investor relations website at https://ir.nrxpharma.com/events beginning at 7:00 AM ET on Monday, September 9, 2024.

What is the venue for the H.C. Wainwright conference where NRx Pharmaceuticals (NRXP) is presenting?

The in-person venue for the H.C. Wainwright 26th Annual Global Investment Conference, where NRx Pharmaceuticals (NRXP) is presenting, is the Lotte New York Palace Hotel in New York City, located at 455 Madison Avenue.